

METHACHOLINE PROVOCATION IN PATIENTS WITH RESIDUAL PLEURO-PULMONARY TUBERCULOUS LESIONS

Thesis

Submitted for Partial Fulfillment of
Master Degree
In
Chest Diseases

By
Ibrahim Aly Mohamed Dwedar
M.B., B.Ch.

Supervised by

Prof. Hussein Aly Hussein

*Professor of Chest Diseases
Faculty of Medicine
Ain Shams University*

Prof. Adel Gomaa Aly

*Professor and Chairman of Chest Dept.
Faculty of Medicine
Ain Shams University*

Dr. Manal Hosny Ahmed


*Ass. Prof. of Chest Diseases
Faculty of Medicine
Ain Shams University*



FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY

1996









1. The first part of the document discusses the importance of maintaining accurate records of all transactions and the role of the accounting system in providing reliable financial information. It also highlights the need for transparency and accountability in financial reporting.

2. The second part of the document focuses on the various methods used to collect and analyze financial data, including the use of statistical techniques and the importance of data integrity. It also discusses the challenges associated with data collection and the need for robust data management systems.

3. The third part of the document explores the different types of financial statements and the role of each in providing a comprehensive view of a company's financial performance. It also discusses the importance of understanding the limitations of these statements and the need for additional information to make informed decisions.

4. The fourth part of the document discusses the various factors that can affect a company's financial performance, including market conditions, management decisions, and external events. It also discusses the importance of understanding these factors and the need for proactive financial management.

5. The fifth part of the document discusses the various methods used to assess a company's financial health, including the use of financial ratios and the importance of understanding the limitations of these methods. It also discusses the challenges associated with financial assessment and the need for robust financial management systems.

6. The sixth part of the document discusses the various methods used to improve a company's financial performance, including the use of financial planning and the importance of understanding the limitations of these methods. It also discusses the challenges associated with financial improvement and the need for robust financial management systems.

7. The seventh part of the document discusses the various methods used to manage a company's financial risk, including the use of financial derivatives and the importance of understanding the limitations of these methods. It also discusses the challenges associated with financial risk management and the need for robust financial management systems.

8. The eighth part of the document discusses the various methods used to ensure the integrity of financial reporting, including the use of internal controls and the importance of understanding the limitations of these methods. It also discusses the challenges associated with financial reporting integrity and the need for robust financial management systems.

9. The ninth part of the document discusses the various methods used to ensure the transparency of financial reporting, including the use of disclosure requirements and the importance of understanding the limitations of these methods. It also discusses the challenges associated with financial reporting transparency and the need for robust financial management systems.

10. The tenth part of the document discusses the various methods used to ensure the accountability of financial reporting, including the use of audit requirements and the importance of understanding the limitations of these methods. It also discusses the challenges associated with financial reporting accountability and the need for robust financial management systems.

Acknowledgment

Thanks to GOD who granted me the ability to perform the work of this thesis and for the helpful opportunities He has prepared for me through my sincere supervisors.

I would like to express my supreme gratitude and respect to Professor Dr. Hussein Aly Hussein, Professor of Chest Diseases, Ain Shams University, for his close supervision and valuable instructions throughout this thesis.

I would like also to express my deep thanks and supreme gratitude to Professor Dr. Adel Gomaa Aly, Professor of Chest Diseases and Chairman of Chest Department, Ain Shams University, for his supervision and encouragement throughout this work.

I appreciate, very much, the kind help and encouragement offered to me by Dr. Manal Hosny Ahmed, Assistant Professor of Chest Diseases, Ain Shams University.

CONTENTS

	Page
Introduction and aim of the work	1
Review of Literature	
Bronchial hyperreactivity	
Definition and historical introduction	3
Mechanisms	5
Methods of assessment	33
Variability in normal subjects	48
Relation to various diseases	53
Therapeutic implication	67
Subjects and Methods	73
Results	83
Discussion	111
Summary and Conclusion	120
References	123
Arabic Summary	

LIST OF FIGURES

Fig. No.	Title	Page
	Figures in subjects and methods	
1	Chest radiograph P.A. view showing; residual tuberculous parenchymal lesion	75
2	Chest radiograph P.A. view showing residual tuberculous pleuro-parenchymal lesion	75
3	Chest radiograph P.A. view showing; residual tuberculous pleural lesion	76
	Figures in results	
1	Graph showing comparison between mean spirometric values before and after bronchial challenge with methacholine in the control group	88
2	Graph showing comparison between mean spirometric values before bronchial challenge with methacholine in all cases and the control group	90
3	Graph showing comparison between mean spirometric values after bronchial challenge with methocholine in all cases and the control group	92
4	Graph showing comparison between mean spirometric values before and after bronchial challenge with methacholine in all cases	94
5	Graph showing comparison between mean spirometric values in positive and negative cases before methacholine challenge test	96
6	Graph showing comparison between mean spirometric values in positive and negative cases after methacholine bronchial challenge	98

7	Graph showing comparison between mean spirometric values before and after bronchial challenge with methacholine in cases with residual pleural lesions	100
8	Graph showing comparison between mean spirometric values before and after bronchial challenge with methacholine in cases with residual parenchymal lesions	102
9	Graph showing comparison between mean spirometric values before and after bronchial challenge with methacholine in cases with both pleural and parenchymal residual lesions	104
10	Graph showing comparison between mean spirometric values baseline and after bronchodilator therapy in positive cases	106

LIST OF TABLES

Tab. No.	Title	Page
	Tables in review and materials & methods	
1	Mechanisms by which the cholinergic nervous system might contribute to bronchial hyperreactivity	8
2	Mechanisms by which the sympathetic nervous system might contribute to bronchial hyperreactivity	10
3	Peptides identified in the lung	11
4	Mechanisms by which the non-adrenergic and non-cholinergic nervous systems might contribute to bronchial hyperreactivity	13
5	Non-specific stimuli used to measure bronchial responsiveness	37
6	Concentrations of methacholine solutions	79
	Tables in results	
1	Distribution of all cases of residual lesions	85
2	Comparison between the mean age and height	86
3	Time of development of bronchial hyperreactivity	86
4	Comparison between mean spirometric values before and after bronchial challenge with methacholine in the control group	87
5	Comparison between mean spirometric values before bronchial challenge with methacholine in all cases and the control group	89
6	Comparison between mean spirometric values after bronchial challenge with methacholine in all cases and the control group	91

7	Comparison between mean spirometric values before and after bronchial challenge with methacholine in all cases	93
8	Comparison between mean spirometric values in positive and negative cases before methacholine bronchial challenge test	95
9	Comparison between mean spirometric values in negative and positive cases after methacholine bronchial challenge test	97
10	Comparison between mean spirometric values before and after bronchial challenge with methacholine in cases with residual pleural lesions	99
11	Comparison between mean spirometric values before and after bronchial challenge with methacholine in cases with residual parenchymal lesions	101
12	Comparison between mean spirometric values before and after bronchial challenge with methacholine in cases with both pleural and parenchymal residual lesions	103
13	Comparison between mean spirometric values baseline and after bronchodilator therapy in positive cases	105

ABBREVIATION

AEFV	Area under the expiratory flow volume curve
BAL	Broncho-alveolar lavage
CDAP	Computer digitized airway phonopneumograph
CGRP	Calcitonin gene related peptide
DRSFEV1	Dose response slope for FEV1
ECF-A	Eosinophil chemotactic factor of anaphylaxis
ECP	Eosinophil cationic protein
EDN	Eosinophil derived neurotoxin
EPO	Eosinophil peroxidase
FEF	Forced expiratory flow
FEV1	Forced expiratory volume in the first second
FRC	Functional residual capacity
FVC	Forced vital capacity
ICAM-1	Intercellular adhesion molecule
Ig	Immunoglobulin
LFA	Lymphocyte function associated antigen
LT	Leukotriene
MBP	Major basic protein
MIC	Methacholine inhalation challenge
NANC	Non-adrenergic, non-cholinergic
NCF	Neutrophil chemotactic factor
NK	Neurokinin
NP	Neuropeptide

PAF	Platelet activating factor
PC20	Provocative concentration at which FEV1 decreases by 20%
PD20	Provocative dose at which FEV1 decreases by 20%
PEFR	Peak expiratory flow rate
PG	Prostaglandin
PGFA	Prostaglandin generating factor of anaphylaxis
PHI	Peptide histadine isoleucine
PHM	Peptide histadine methionine
sGaw	Specific airway conductance
SP	Substance P
TCPO2	Transcutaneous monitoring of blood oxygen pressure
TGV	Thoracic gas volume
VIP	Vaso-active intestinal peptide